source
- Neurosterix raises $105M Series B to advance oral M4 schizophrenia drug and adds former Karuna leadersNeurosterix, a spinout from Addex Therapeutics, announced a $105 million Series B financing. The round was led by RTW Investments with participation from GV, Janus Henderson Investors and others. A…
- Bristol Myers Squibb reshuffles R&D leadership as chief research officer departs and CMO takes over combined unitBristol Myers Squibb announced a restructuring of its research and development organization, merging the separate research and development divisions into a single unit. The new combined R&D unit w…